Skip to content
Credit reportVerdict and grounds
Made on 17-11-2026 at 07:17
Reference CK-0739549477-20261117

Axepharma

ActivePrivate limited company0739.549.477Beverhoutsveldstraat 64, 8730 Beernem
Retail sale of pharmaceutical products (NACE 47730) · founded in 2019 · 2 employees on 31-12-2025

Sources: the KBO register on 17-11-2026; the National Bank, 2025 annual accounts filed on 26-05-2026; the Belgian Official Gazette, latest deed of 16-12-2019.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,287 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€151,840
▲ 4.7% against 2024
Net result
€65,629
▲ 12.8% against 2024
Equity
€310,130
▲ 0.1% against 2024
Cash
€177,525
▲ 79.4% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. Axepharma made a profit in every financial year since 2020.Annual accounts 2020 to 2025 page 2
  2. Equity stands at €310,130, or 70.1% of the balance sheet total of €442,129.Annual accounts 2025 page 2
  3. Axepharma paid out €63,000 in dividends, 96% of the profit of 2025. Because of the dividend, solvency fell from 79.7% to 70.1%.Annual accounts 2025 page 2
  4. The 2025 accounts reached the National Bank 66 days before the end of the term.National Bank, filing of 26-05-2026 page 4

Representation

The signing rule is in the deed of 16-12-2019.

Articles of association, Belgian Official Gazette of 16-12-2019, deed 19348851

Ownership

founded Axepharma by deed of 16-12-2019. There is one other shareholder.

Deed of 16-12-2019

Axepharma · 0739.549.477 · credit report of 17-11-2026Page 1 of 5
Axepharma0739.549.477 · report of 17-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin euro

2021147,3852022152,8672023129,5522024145,0522025151,840202167,606202269,445202349,132202458,188202565,629
gross marginnet result

Equity and debtsin euro

20212022202320242025310,130131,999
equitydebts

Cashin euro

202138,044202299,099202349,509202498,9782025177,525
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin€147,385€152,867€129,552€145,052€151,840
Operating result€106,350€113,933€85,409€85,882€95,976
Net result€67,606€69,445€49,132€58,188€65,629
Balance sheet at the closing date
Equity€135,400€204,846€253,978€309,856€310,130
Debts€100,539€84,391€76,531€78,910€131,999
Debts due after more than one year€40,742€21,284€1,645--
Debts due within one year€59,797€63,106€74,886€77,160€130,494
Cash€38,044€99,099€49,509€98,978€177,525
Balance sheet total€235,940€289,236€330,509€388,765€442,129
Operations
Employees in full-time equivalents2.02.02.02.01.1
Ratios
Solvency57.4%70.8%76.8%79.7%70.1%
Liquidity3.824.494.304.963.32

Source: Annual accounts 2025, abbreviated format, filed on 26-05-2026 (2026-00120809); Annual accounts 2024, micro format, filed on 01-07-2025 (2025-00209307); Annual accounts 2021 to 2023, filed from 28-07-2022 to 31-07-2024 (2022-20236399, 2023-00319863, 2024-00321999).

The operating result of 2025 is 12% higher than in 2024.

Debts rose by €53,090 in 2025. A dividend stands among the debts on the balance sheet date until it is paid.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

Axepharma · 0739.549.477 · credit report of 17-11-2026Page 2 of 5
Axepharma0739.549.477 · report of 17-11-2026

Board, signature and ownership

Position on 17-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the deed of 16-12-2019.

Articles of association, Belgian Official Gazette of 16-12-2019, deed 19348851

Board

two directors in office
Directorsince 11-12-2019
term without a fixed enddeed of 16-12-2019
Directorsince 01-01-2020

Ownership and group

Shareholders

founded Axepharma by deed of 16-12-2019. founded Axepharma by deed of 16-12-2019.

Deed of 16-12-2019

Axepharma · 0739.549.477 · credit report of 17-11-2026Page 3 of 5
Axepharma0739.549.477 · report of 17-11-2026

Events and comparison

Every event since the founding, newest first

Annual accounts 2025 filed, 66 days before the deadline.

NBB filing

Annual accounts 2024 filed, 30 days before the deadline.

NBB filing

Registered in the Peppol Directory. Reachable for e-invoices through 0208:0739549477.

Annual accounts 2023 filed. On the deadline day.

NBB filing

Weakest financial year. The net result drops to €49,132, the lowest from 2020 to 2025. It recovers the following year.

Financial

Annual accounts 2022 filed, 7 days late.

NBB filing

Highest result from 2020 to 2025. The operating result of €113,933 and the net result of €69,445 are both a record.

Financial

Equity above €200,000. With a profit in every financial year since 2020, equity grows to €204,846.

Financial

Annual accounts 2021 filed, 3 days before the deadline.

NBB filing

Equity above €100,000. With a profit in every financial year since 2020, equity grows to €135,400.

Financial

Annual accounts 2020 filed, 9 days before the deadline.

NBB filing

Incorporation. Founding capital of €10,000, 1,000 shares. Founded by and . (director) and (director) appointed. Published on 16-12-2019.

Gazette, deed 19348851

First establishment. Smedenstraat 73, Bruges.

Comparable companies, two years later

In July 2024, 26,977 companies had the same profile as Axepharma has now: micro, 5 to 10 years old, solvency 30% or more and a profit of 5% of the balance sheet or more. Two years later 94.8% were still trading, 3.6% had stopped another way and 1.6% had gone bankrupt.

still trading 94.8% stopped another way 3.6% bankrupt 1.6%

In 2025, Axepharma had a higher net result than 61% of the 13,256 companies in the retail trade sector (NACE 47).

Other findings

Peppol

Reachable for e-invoices since 08-11-2024, under 0208:0739549477.

Sanctions lists

Staff

2 employees on 31-12-2025, 1.1 full-time equivalents on average over the year.

Axepharma · 0739.549.477 · credit report of 17-11-2026Page 4 of 5
Axepharma0739.549.477 · report of 17-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units17-11-2026KBO 0739.549.477
National Bank of BelgiumAnnual accounts 2025, abbreviated format26-05-20262026-00120809
National Bank of BelgiumAnnual accounts 2024, micro format01-07-20252025-00209307
National Bank of BelgiumAnnual accounts 2021 to 202328-07-2022 to 31-07-20242022-20236399, 2023-00319863, 2024-00321999
Belgian Official GazetteArticles of association with the signing rule16-12-2019deed 19348851
Peppol DirectoryRegistration for e-invoices08-11-20240208:0739549477
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name16-11-2026no match
CheckedChecked score, bankruptcy probability, credit, comparable companies16-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 16-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

Axepharma · 0739.549.477 · credit report of 17-11-2026Page 5 of 5